SFSamuel Finnikin

Samuel Finnikin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Samuel Finnikin has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardiovascular Risk Estimation and Statin Adherence: A Historical Cohort Study

    by Samuel Finnikin, Brian Willis, Tim Evans, Brian Finney, Kwan Nok Chris Hui, Rani Khatib, Tom Marshall

    Background.: Adherence to statins for the primary prevention of cardiovascular disease (CVD) is low but may be improved through shared decision making (SDM). CVD risk estimation is fundamental to SDM at statin initiation, and the absence of a CVD risk score may indicate that SDM has not taken place. This study explores statin initiation decisions by investigating whether CVD risk is associated with adherence to statins and CVD outcomes. Design.: A cohort of statin-naïve patients aged 40 to 84 y initiated on statins for primary prevention between 2017 and 2020 was identified and categorized by the presence or absence of a CVD risk score at statin initiation. Multivariable modeling determined the association between CVD risk score and statin adherence and persistence. A secondary analysis investigated the relationship with CVD outcomes and death. Results.: A total of 255,730 patients were included with a mean follow-up of 4.6 y. The presence of a CVD risk score (67.7% of patients) was associated with a 7% increase in adherence and an 8% reduction in discontinuations as well as a 15% reduction in CVD and all-cause mortality. Conclusion.: The presence of a CVD risk score is associated with improvements in both adherence and persistence, which could indicate that the quality of initiation consultations, and a focus on SDM, improves the utility of statins. In addition, CVD risk scoring is associated with a large decrease in CVD/death, which cannot fully be explained by improvements in statin adherence and persistence, an important finding necessitating further investigation. Implications.: Efforts to improve the integration of CVD risk scores and SDM in statin initiation consultations may significantly improve statin utilization and CVD outcomes. Highlights: We present a comprehensive assessment of the adherence to and persistence with statins for the primary prevention of CVD, which, for the first time, is linked to the presence or absence of CVD risk scoring. CVD risk scoring is associated with improvements in both adherence and persistence as well as significant reductions in CVD and all-cause mortality. There should be renewed focus on the content of statin initiation consultations ensuring that CVD risk is communicated using a shared decision-making approach. Further consideration should be given to the important discrepancy in CVD and death seen when CVD risk scoring is, and is not, used in practice.

  • Reply to Shih-Wei Lai: Gout flares, serum urate, and lifestyle modification

    by Samuel Finnikin, Christian D. Mallen, Edward Roddy

  • Open Access

    Cohort study investigating the natural history and management of sore throat and tonsillitis among adults in UK general practice

    by Samuel Finnikin, James O’HAra, Tom Marshall

    Background: Recurrent sore throat affects a small minority of adults but can cause substantial morbidity. Evidence to guide tonsillectomy eligibility in adults is limited, and current criteria are extrapolated from paediatric populations. We aimed to describe the epidemiology, management, and prognosis of adult sore throat in UK primary care. Methods: Using CPRD Aurum (2010–2020 adults with a first coded episode of sore throat or tonsillitis were identified and matched to controls. Episode frequency, antibiotic use, ENT referral, and tonsillectomy were analysed. Predictors of recurrent episodes (≥3 in 365 days), referral, and tonsillectomy were assessed using time-to-event, multinomial logistic, and multilevel mixed-effects regression models. Findings: Of 4.45 million adults, 1.70 million (38.3%) had ≥1 episode; most (61.5%) had only one, but 4.1% experienced ≥3 within 1 year. Recurrent episodes were more common in younger females and those from more deprived areas. Only 21,869 patients (0.5% of the exposed cohort) underwent tonsillectomy, and just 25.7% of these met Paradise criteria at any time; conversely, only 13.9% of those meeting criteria underwent surgery. Patients who had a tonsillectomy tended to be younger, female, and from less deprived areas. Pre-tonsillectomy episode rates were unexpectedly low, but the data indicated that individuals with high baseline burden continue to experience elevated episode rates over several years. Conclusions: Recurrent sore throat is uncommon, but those affected face substantial disease burden. Current tonsillectomy patterns are poorly aligned with disease burden and show inequities by deprivation. Earlier identification of adults likely to develop recurrent episodes, and more timely surgical intervention, may improve patient outcomes and the cost-effectiveness of tonsillectomy.

  • Open Access

    Gout flares, serum urate and seasonality: a descriptive cohort study

    by Samuel Finnikin, Christian D. Mallen, Edward Roddy

    Aims: To investigate the relationship between serum urate levels and gout flares and how these vary at different times of the year. Methods: A cohort of people with incident gout was established using a large UK primary care database (Clinical Practice Research Database). Clinician-recorded gout flares and serum urate (SU) measurements were identified and described using joinpoint linear regression modelling. The relationship between SU level, flare frequency, month of the year and mean monthly temperatures was explored and correlations tested using Pearson correlation coefficients. Results: 249,157 individuals (mean follow-up 6.7 years) experienced 417,101 flares and had 341,457 SU measurements (mean SU 437 µmol/L, standard deviation (SD) 106 µmol/L). SU levels peaked the day before a flare (487 µmol/L). Mean SU in the year preceding a flare was 474 µmol/L compared with 432 µmol/L in the year post-flare. SU levels did not near pre-flare levels in the year following a flare. Flares were most frequent, and SU was highest, in the summer months (June to August). The correlation co-efficient between flares and months of the year was 0.94, whereas the correlation with temperature was less strong (0.70). Conclusions: SU measurement in the year following a gout flare is not indicative of the peak (pre-flare) SU levels that an individual may have experienced. Clinicians should consider this when considering SU measurements in the diagnosis of gout. Patients may find it helpful to be informed of the seasonality of gout flares and advised to take extra caution to reduce the risk of flares during summer months. Keypoints • Serum urate (SU) levels drop precipitously during gout flares and remain low for several months. • Correlations exist between flare rate and summer months, and with seasonal variation in SU levels. • Clinicians should be aware of how gout flares affect SU when interpreting SU levels.


  • Open Access

    Cardiovascular risk estimation and statin adherence An historical cohort study

    by Samuel Finnikin, Brian Willis, Tim Evans, Brian Finney, Kwan Nok Chris Hui, Rani Khatib, Tom Marshall

    Background Adherence to statins for the primary prevention of cardiovascular disease (CVD) is low. There is evidence that some facets of the initiation consultation, or the initiating clinician, are associated with adherence. CVD risk estimation is fundamental to statin initiation and shared decision making (SDM), because the benefits of statins are proportional to CVD risk. Absence of a recorded CVD risk score before statin initiation therefore indicates SDM is unlikely. This study investigates whether, in primary prevention, SDM, using CVD risk score as a proxy measure, is associated with adherence to statins and CVD outcomes. Method A cohort of statin naïve patients aged 40-84 years initiated on statins for primary prevention between 2017 and 2020 was identified and categorised by the presence or absence of a CVD risk score at statin initiation. Statin adherence and persistence was determined from subsequent statin prescriptions. Multivariable modelling, accounting for potential confounders determined the association between a recorded CVD risk score and statin adherence and persistence. A secondary analysis investigated the relationship with subsequent CVD outcomes and death. Results 255,730 patients were included with a mean follow up of 4.6 years. 67.7% had a CVD risk score coded. The presence of a CVD risk score increased odds of adherence at the end of year one by 7% and reduced the chances of discontinuation by 8%. The composite outcome of CVD and all-cause mortality was decreased by 21% when a CVD risk score was present. Conclusion When a statin is initiated in the presence of a CVD risk score there is a small, but significant improvement in both adherence and persistence which could indicate that the quality of initiation consultations, and a focus on SDM, improves the utility of statins. Additionally, CVD risk scoring is associated with a large decrease in CVD/death which cannot fully be explained by improvements in statin adherence and persistence; an important finding necessitating further investigation. What is new? We present a comprehensive assessment of the adherence to and persistence with statins for the primary prevention of CVD which, for the first time, is linked to the presence or absence of CVD risk scoring. CVD risk scoring is associated with improvements and both adherence and persistence as well as significant reductions in CVD and all-cause mortality. What are the clinical implications? There should be renewed focus on the content of statin initiation consultations ensuring that CVD risk is communicated using a shared decision-making approach. Further consideration should be given to the important discrepancy in CVD and death seen when CVD risk scoring is, and is not, used in practice.

  • Navigating ‘not doing’ in primary care: could more explicit guidelines on record keeping help to ease clinician anxiety?

    by Claire Hastings, Samuel Finnikin, Julian Treadwell, Carolyn Tarrant, Natalie Armstrong

    There are increasing concerns about medical overuse, including over-prescription, overdiagnosis, unnecessary referrals, and a recognition of the harm it could cause patients. Medical overuse is complex, driven by time pressures, care discontinuity, patient expectations, team culture, misuse of guidelines, fear of complaints, and peer criticism.2 HCPs often worry more about being criticised for ‘not doing’ than unnecessary interventions, despite the risks associated with both scenarios.2 Anxiety over patients’ decisions to ‘not do’ something, along with fear of reprisals, may fuel defensive practices. Robust record keeping could be an important facilitator in reducing clinician anxiety and decreasing medical overuse.


  • Open Access

    Cardiovascular risk estimation and statin adherence: a historical cohort study protocol

    by Samuel Finnikin, Brian Willis, Rani Khatib, Tim Evans, Tom Marshall

    Background: Adherence to statins for the primary prevention of cardiovascular disease (CVD) is low. There is evidence that some facets of the initiation consultation, or the initiating clinician, are associated with adherence. CVD risk estimation is fundamental to statin initiation and shared decision making (SDM), because the benefits of statins are proportional to CVD risk. Absence of a recorded CVD score before statin initiation therefore indicates that SDM is unlikely. Aim: To investigate whether SDM, using the CVD risk score as a proxy measure, is associated with adherence to statins and CVD outcomes. Design & setting: A retrospective cohort study using a database of English primary care records. Method: The cohort will include statin-naïve patients aged 40–84 years initiated on statins for primary prevention between 2017 and 2020, categorised by the presence or absence of a CVD risk score at statin initiation. Statin adherence and persistence will be determined from subsequent statin prescriptions. Multivariable modelling, accounting for potential confounders, will determine the association between a recorded CVD risk score and subsequent statin adherence and with statin persistence. A secondary analysis will investigate the relationship to subsequent CVD outcomes and death. Conclusion: This research uses a record of CVD risk score as a proxy for SDM, to investigate the link between SDM and medication adherence. It will shed light on the relationship between how the initiation consultation is performed and subsequent adherence and persistence with treatment.


  • Open Access

    Safety-netting advice documentation in out-of-hours primary care: a retrospective cohort from 2013 to 2020

    by Peter J Edwards, Samuel Finnikin, Fay Wilson, Ian Bennett-Britton, Andrew Carson-Stevens, Rebecca K Barnes, Rupert A Payne

    Background: Providing safety-netting advice (SNA) in out-of-hours (OOH) primary care is a recognised standard of safe care, but it is not known how frequently this occurs in practice. Aim: Assess the frequency and type of SNA documented in OOH primary care and explore factors associated with its presence. Design and setting: This was a retrospective cohort study using the Birmingham Out-of-hours general practice Research Database. Method: A stratified sample of 30 adult consultation records per month from July 2013 to February 2020 were assessed using a safety-netting coding tool. Associations were tested using linear and logistic regression. Results: The overall frequency of SNA per consultation was 78.0% (1472/1886), increasing from 75.7% (224/296) in 2014 to 81.5% (220/270) in 2019. The proportion of specific SNA and the average number of symptoms patients were told to look out for increased with time. The most common symptom to look out for was if the patients’ condition worsened followed by if their symptoms persisted, but only one in five consultations included a timeframe to reconsult for persistent symptoms. SNA was more frequently documented in face-to-face treatment-centre encounters compared with telephone consultations (odds ratio [OR] 1.77, 95% confidence interval [CI] = 1.09 to 2.85, P = 0.02), for possible infections (OR 1.53, 95% CI = 1.13 to 2.07, P = 0.006), and less frequently for mental (versus physical) health consultations (OR 0.33, 95% CI = 0.17 to 0.66, P = 0.002) and where follow-up was planned (OR 0.34, 95% CI = 0.25 to 0.46, P <0.001). Conclusion: The frequency of SNA documented in OOH primary care was higher than previously reported during in-hours care. Over time, the frequency of SNA and proportion that contained specific advice increased, however, this study highlights potential consultations where SNA could be improved, such as mental health and telephone consultations.


  • Statins, risk, and personalised care

    by Sam Finnikin, Brian Finney, Rani Khatib, James McCormack

    Sam Finnikin and colleagues argue that guidelines should focus less on population level risk thresholds and more on shared decision making conversations based on individualised risk and patient preferences


  • Open Access

    Cohort study investigating gout flares and management in UK general practice

    by Samuel Finnikin, Christian D. Mallen, Edward Roddy

    Background: Gout is the most common inflammatory arthritis and is almost exclusively managed in primary care, however the course and severity of the condition is variable and poorly characterised. This research aims improve understanding about the frequency of, and factors associated with, gout flares in the UK and characterise the factors associated with the initiation of ULT. Methods: Using the Clinical Practice Research Database, patients with a coded incident gout diagnosis without a prior prescription for urate-lowering therapy (ULT) were identified. Gout flares post diagnosis and ULT initiation were identified through prescribing and coded data. Patient characteristics, co-morbidities and co-prescribing were co-variants. Factors associated with gout flares and ULT initiation were analysed using cox-proportional hazard model and logistic regression. Results: Fifty-one thousand seven hundred eighty-four patients were identified: 18,605 (35.9%, 95%CI 35.5–36.3%) had experienced ≥ 1 recurrent flare, 17.4% (95%CI 17.1–17.8%) within 12 months of diagnosis. Male sex, black ethnicity, higher BMI, heart failure, CKD, CVD and diuretic use were associated with flares, with the highest HR seen with high serum urate levels (≥ 540 µmol/L HR 4.63, 95%CI 4.03–5.31). ULT initiation was associated with similar variables, although higher alcohol intake and older age were associated with lower odds of ULT initiation but were not associated with flares. ULT was initiated in 27.7% (95%CI 27.3–28.0%): 5.7% (95%CI 5.5–5.9%) within 12 months of diagnosis. ULT initiation rates were higher in patients with recurrent flares. Conclusion: Approximately one in six people with incident gout had a second flare within 12 months. Factors associated with flare recurrence and ULT initiation were similar, but ULT initiation occurred later after diagnosis than previously thought.